Overview

Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy

Status:
Completed

Trial end date:
2010-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test in a pilot trial the efficacy and tolerance of sirolimus oral (at low doses) in patient to treat poor-prognosis IgA Nephropathy.

Phase:

Phase 2

Details

Lead Sponsor:

Josep m Cruzado

Collaborator:

Wyeth is now a wholly owned subsidiary of Pfizer

Treatments:

Angiotensin-Converting Enzyme Inhibitors
Everolimus
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Sirolimus